Author:
Resta Lee P.,Pili Roberto,Eisenberger Mario A.,Spitz Avery,King Serina,Porter Jennifer,Franke Amy,Boinpally Ramesh,Carducci Michael A.,Sweeney Christopher J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference12 articles.
1. Thompson WJ, Piazza GA, Li H et al (2000) Exisulind induction of apoptosis involves guanosine 3′, 5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60:3338–3342
2. Whitehead CM, Earle KA, Xu S et al (2002) CP461 in an orthotopic human NSCLC rat model involves phosphodiesterase targeting, apoptosis induction, G2/M block and anti-proliferation. Proc Am Assoc Cancer Res 43:924
3. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216
4. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148–1159
5. Ryan CW, Stadler WM, Vogelzang NJ (2005) A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. BJU Int 95(7):963–968
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献